

FreeStyle Libre systems help further improve A1C in patients receiving GLP-1 therapy^{*1}



Patients on GLP-1 therapy who added FreeStyle Libre systems had significant, additional A1C reductions after CGM initiation, **regardless of GLP-1** or insulin therapy type¹.

Study Objective & Design:


- Real-world analysis of EHR claims
- Evaluate changes in A1C with the addition of FreeStyle Libre systems among people currently using GLP-1 therapy
- Data from a large U.S. health database

Patient Population:

- Adults with T2D
- Baseline A1C $\geq 8\%$
- Had at least one GLP-1 therapy within 180 days before FreeStyle Libre systems initiation

Method:

- Δ A1C from baseline assessed at 6 months after initial FreeStyle Libre systems acquisition for overall patient population and subgroups based on GLP-1 and insulin therapy type



Significant A1C reductions seen after initiating FreeStyle Libre systems even in patients using GLP-1 therapy >1 year prior to CGM.

Patients using a GLP-1 experienced significant improvements in A1C after initiating FreeStyle Libre systems, regardless of GLP-1 duration, GLP-1 type, or insulin therapy type¹.

Abbreviation: T2D=type 2 diabetes.

^{*}Real-world study that utilized a linked electronic health records (EHR)-claims database and included adults with T2D and HbA1c $\geq 8\%$ who acquired their first GLP-1 2018-2022.

1. Miller, E. *Diabetes Therapy* (2024): <https://doi.org/10.1007/s13300-024-01619-1>. See next page for Important Safety Information.



Initiating FreeStyle Libre systems within 30 days of starting GLP-1 therapy provides significantly greater clinical results^{*1}

Study Objective & Design:

- Real-world analysis of EHR claims
- Compare changes in A1C among people using GLP-1 with and without FreeStyle Libre systems
- Data from a large U.S. health database

Patient Population:


- Adults with T2D
- Baseline A1C $\geq 8\%$
- CGM start within ± 30 days of starting GLP-1 therapy (GLP-1 & FreeStyle Libre systems group)

Method:

- Cohorts were matched on baseline insulin therapy, age, sex, baseline A1C, and GLP-1 type
- Δ A1C was compared between matched groups at 6 months

Starting FreeStyle Libre systems **within 30 days** of GLP-1 therapy showed significantly greater A1C reduction than GLP-1 therapy alone^{*1}.

ALL MATCHED PATIENTS



Patients combining FreeStyle Libre systems within 30 days of starting GLP-1 therapy experienced:

- 0.37 ($p<0.001$)[†] incremental A1C reduction vs. GLP-1 alone
- Significantly higher proportion reaching A1C $< 8\%$ vs. GLP-1 alone (59.8% vs. 53.8% $p=0.07$)

Recommend FreeStyle Libre systems today to your patients on GLP-1 therapy to help improve glycemic control.



^{*}This real-world study included 24,246 subjects in the GLP-1 group and 478 subjects in the GLP-1 and FreeStyle Libre systems group prior to matching. Cohorts were matched on baseline insulin therapy, age, sex, A1C, and GLP-1 type. Paired change in A1C was compared between matched groups at six months. [†]Difference in Difference = -0.37 $p<0.001$.

1. Wright, E. *Diabetes Technology & Therapeutics* (2024): <https://doi.org/10.1089/dia.2024.0015>.

IMPORTANT SAFETY INFORMATION

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.freestyleprovider.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott.

© 2024 Abbott. ADC-89778 v2.0 08/24